Business UpdateApr 13, 2026, 08:34 AM
Optum/UHC/UBH Expands NeuroStar TMS Access to PMHNPs in 26 States
AI Summary
Neuronetics, Inc. announced that Optum/United Healthcare/United Behavioral Health (Optum/UHC/UBH) has updated its Transcranial Magnetic Stimulation (TMS) clinical policy. The updated policy now permits psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy, a role previously limited to psychiatrists. This expansion significantly increases access to NeuroStar therapy for 34.8 million Optum/UHC/UBH commercial covered lives across 26 states and Washington, D.C., which is expected to drive greater adoption and utilization of Neuronetics' NeuroStar Advanced Therapy.
Key Highlights
- Optum/UHC/UBH policy now allows PMHNPs to order, supervise, and administer TMS therapy.
- Policy expands access to NeuroStar therapy for 34.8 million Optum/UHC/UBH commercial covered lives.
- Access expanded across 26 states and Washington, D.C.
- NeuroStar TMS therapy has up to an 83% response rate and 62% remission rate for MDD.
- Neuronetics is the only TMS company with a dedicated health policy team.